Continued treatment with secukinumab is associated with high retention or regain of response
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Dermatology"
DOI: 10.1111/bjd.17991
Abstract: Conventional analyses present aggregate data, masking late responders and efficacy reductions. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)‐17A, shows sustained efficacy in moderate‐to‐severe psoriasis. read more here.
Keywords: secukinumab associated; associated high; retention regain; high retention ... See more keywords